The current organization of the eNose Company was founded in 2013. The eNose Company is mainly focused on exhaled breath analysis of patiënts for disease screening. After a number of pilot- studies in oncology, infectional- and neurological diseases, the eNose Company is fully focused on certain indications like Colon Cancer, Lung cancer, Tuberculosis and Fasting. In 2014, The eNose Company has received CE-mark for the Aeonose device and in 2015 the Company was ISO 13485 certificated.